logo-360

Best AI in Drug Discovery Vendors 2024

Report Code: 360-HIT 7445

Published Date: Nov 2023

Free Sample

Comparing 24 vendors in AI in Drug Discovery across 0 criteria.

The Artificial Intelligence (AI) in drug discovery Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Artificial Intelligence (AI) in drug discovery. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 40 companies of which the Top 24 Artificial Intelligence (AI) in drug discovery Companies were categorized and recognized as the quadrant leaders.

Market Leadership Quadrant
Download Free Sample
Show More

1.1    STUDY OBJECTIVES
1.2    MARKET DEFINITION
        1.2.1    INCLUSIONS AND EXCLUSIONS
1.3    MARKET SCOPE
       1.3.1    MARKET SEGMENTATION
       1.3.2    REGIONAL SCOPE
       1.3.3    YEARS CONSIDERED

     2.1    DRIVERS
            2.1.1    Growing cross-industry collaborations and partnerships
            2.1.2    Growing need to reduce time and cost of drug discovery and development
            2.1.3    Patent expiry of several drugs
        2.2    RESTRAINTS
            2.2.1    Shortage of AI workforce and ambiguous regulatory guidelines for medical software
        2.3    OPPORTUNITIES
            2.3.1    Growing biotechnology industry
            2.3.2    Emerging markets
            2.3.3    Focus on developing human-aware AI systems
        2.4    CHALLENGES
            2.4.1    Limited availability of data sets
    2.5    PORTER’S FIVE FORCES ANALYSIS
        2.5.1    INTENSITY OF COMPETITIVE RIVALRY
        2.5.2    BARGAINING POWER OF BUYERS
        2.5.3    BARGAINING POWER OF SUPPLIERS
        2.5.4    THREAT OF SUBSTITUTES
        2.5.5    THREAT OF NEW ENTRANTS
    2.6    ECOSYSTEM/MARKET MAP

   3.1    KEY PLAYER STRATEGIES/RIGHT TO WIN
   3.2    REVENUE ANALYSIS
   3.3    MARKET SHARE ANALYSIS
   3.4    COMPANY EVALUATION MATRIX
        3.4.1    STARS
        3.4.2    EMERGING LEADERS
        3.4.3    PERVASIVE PLAYERS
        3.4.4    PARTICIPANTS
        3.4.5    COMPANY FOOTPRINT
   3.6    COMPETITIVE SCENARIOS AND TRENDS
        3.6.1    PRODUCT LAUNCHES & ENHANCEMENTS
        3.6.2    DEALS
        3.6.3    OTHER DEVELOPMENTS

  4.1    KEY PLAYERS
        4.1.1    NVIDIA CORPORATION
            4.1.1.1    Business overview
            4.1.1.2    Products/Solutions/Services offered
            4.1.1.3    Recent developments
            4.1.1.4    MnM view
            4.1.1.4.1    Key Strengths/Right to win
            4.1.1.4.2    Strategic choices made
            4.1.1.4.3    Weaknesses & competitive threats
        4.1.2    EXSCIENTIA
            4.1.2.1    Business overview
            4.1.2.2    Products/Solutions/Services offered
            4.1.2.3    Recent developments
            4.1.2.4    MnM view
            4.1.2.4.1    Key Strengths/Right to win
            4.1.2.4.2    Strategic choices made
            4.1.2.4.3    Weaknesses & competitive threats
        4.1.3    GOOGLE
            4.1.3.1    Business overview
            4.1.3.2    Products/Solutions/Services offered
            4.1.3.3    Recent developments
            4.1.3.4    MnM view
            4.1.3.4.1    Key Strengths/Right to win
            4.1.3.4.2    Strategic choices made
            4.1.3.4.3    Weaknesses & competitive threats
        4.1.4    BENEVOLENTAI
            4.1.4.1    Business overview
            4.1.4.2    Products/Solutions/Services offered
            4.1.4.3    Recent developments
            4.1.4.4    MnM view
            4.1.4.4.1    Key Strengths/Right to win
            4.1.4.4.2    Strategic choices made
            4.1.4.4.3    Weaknesses & competitive threats
        4.1.5    RECURSION
            4.1.5.1    Business overview
            4.1.5.2    Products/Solutions/Services offered
            4.1.5.3    Recent developments
            4.1.5.4    MnM view
            4.1.5.4.1    Key Strengths/Right to win
            4.1.5.4.2    Strategic choices made
            4.1.5.4.3    Weaknesses & competitive threats
        4.1.6    INSILICO MEDICINE
            4.1.6.1    Business overview
            4.1.6.2    Products/Solutions/Services offered
            4.1.6.3    Recent developments
        4.1.7    SCHRÖDINGER, INC.
            4.1.7.1    Business overview
            4.1.7.2    Products/Solutions/Services offered
            4.1.7.3    Recent developments
        4.1.8    MICROSOFT CORPORATION
            4.1.8.1    Business overview
            4.1.8.2    Products/Solutions/Services offered
            4.1.8.3    Recent developments
        4.1.9    ATOMWISE INC.
            4.1.9.1    Business overview
            4.1.9.2    Products/Solutions/Services offered
            4.1.9.3    Recent developments
        4.1.10    ILLUMINA, INC.
            4.1.10.1    Business overview
            4.1.10.2    Products/Solutions/Services offered
            4.1.10.3    Recent developments
        4.1.11    NUMEDII, INC.
            4.1.11.1    Business overview
            4.1.11.2    Products/Solutions/Services offered
        4.1.12    XTALPI INC.
            4.1.12.1    Business overview
            4.1.12.2    Products/Solutions/Services offered
            4.1.12.3    Recent developments
        4.1.13    IKTOS
            4.1.13.1    Business overview
            4.1.13.2    Products/Solutions/Services offered
            4.1.13.3    Recent developments
        4.1.14    TEMPUS LABS
            4.1.14.1    Business overview
            4.1.14.2    Products/Solutions/Services offered
            4.1.14.3    Recent developments
        4.1.15    DEEP GENOMICS, INC.
            4.1.15.1    Business overview
            4.1.15.2    Products/Solutions/Services offered
            4.1.15.3    Recent developments
        4.1.16    VERGE GENOMICS
            4.1.16.1    Business overview
            4.1.16.2    Products/Solutions/Services offered
            4.1.16.3    Recent developments
        4.1.17    BENCHSCI
            4.1.17.1    Business overview
            4.1.17.2    Products/Solutions/Services offered
            4.1.17.3    Recent developments
        4.1.18    INSITRO
            4.1.18.1    Business overview
            4.1.18.2    Products/Solutions/Services offered
            4.1.18.3    Recent developments
        4.1.19    VALO HEALTH
            4.1.19.1    Business overview
            4.1.19.2    Products/Solutions/Services offered
            4.1.19.3    Recent developments
        4.1.20    BPGBIO, INC.
            4.1.20.1    Business overview
            4.1.20.2    Products/Solutions/Services offered
            4.1.20.3    Recent development
    4.2    OTHER EMERGING PLAYERS
        4.2.1    PREDICTIVE ONCOLOGY, INC.
        4.2.2    IQVIA INC.
        4.2.3    TENCENT HOLDINGS LIMITED
        4.2.4    BIOAGE LABS
        4.2.5    ARIA PHARMACEUTICALS, IN

 
License Options
Enterprise License Single User License
What’s
Included in
This Report

Company Profiles

Strategy, financials, growth, and SWOT

Market Insights

Visual quadrant of competitors and leaders

Benchmarking

Compare by product, region, and end-user

Lead Gen Add-on

Use the quadrant to attract clients
  • Analyst-led
  • One-time payment
  • Instant Access
Latest Industry News
Company List Full List

Company List +

Icon Company
Icon Headquarters
Icon Year Founded
Icon Holding Type
Atomwise Inc. San Francisco, USA 2015 Private
BPGbio, Inc. Framingham, USA 2006 Private
BenchSci Toronto, Canada 2015 Private
BenevolentAI UK 2013 Public
Deep Genomics Toronto, Canada 2014 Private
 
Frequently Asked Questions (FAQs)
AI in drug discovery refers to the use of artificial intelligence technologies, such as machine learning, deep learning, and natural language processing, to streamline and enhance the drug discovery and development process.
AI accelerates drug discovery by analyzing large datasets, identifying potential drug candidates, optimizing chemical structures, predicting biological responses, and reducing time and costs associated with traditional methods.
Increasing adoption of AI by pharmaceutical companies. Partnerships between biotech firms and AI technology providers. Use of AI to repurpose existing drugs. Expansion of computational biology and biopharma collaborations.
Rising R&D costs in drug development. The need for more efficient and accurate discovery processes. Availability of big data and advancements in computational power. Supportive regulatory environment for AI technologies in healthcare.
High initial investment costs. Lack of standardization in data collection and processing. Limited availability of skilled professionals in AI and biotechnology. Regulatory and ethical concerns.
The success of AI models relies heavily on the quality, diversity, and volume of data. Poor data can lead to inaccurate predictions and less effective drug candidates.
Major players include companies like BenevolentAI, Insilico Medicine, Exscientia, Atomwise, Recursion Pharmaceuticals, and collaborations between tech giants like IBM, Google, and Microsoft with biotech firms.
The market is expected to grow significantly, driven by increased adoption across pharmaceutical and biotech sectors, with a compound annual growth rate (CAGR) exceeding 30% in the next five years.
Integration of quantum computing for more complex drug modeling. Improved explainability and transparency in AI algorithms. Wider adoption of AI in clinical trials and personalized medicine.
 
 

360 quadrants

360 Quadrants is a scientific research methodology by MarketsandMarkets to understand market leaders in 6000+ micro markets

Connect
©2025 360Quadrants, All rights reserved.

360 quadrants

360 Quadrants is a scientific research methodology by MarketsandMarkets to understand market leaders in 6000+ micro markets

Email : [email protected]

Quick Links
logo-360
  • saved

    You haven’t saved anything yet

    To save, search for Vendors by
    Name or Category, then tap the heart